Navigating the Treatment Landscape for ROS1+ NSCLC
Physician’s Weekly spoke with Luis Raez, MD, to learn more about an FDA-approved targeted therapy option for patients with advanced ROS1+ NSCLC.
Feb 4, 2025
Peer to Peer: ROS1+ NSCLC
Physician’s Weekly spoke with several healthcare providers to discuss ROS1+ non-small cell lung cancer and considerations for HCPs.
Sponsored Content Provided by:
Tailoring ROS1+ NSCLC Treatment: The Role of Biomarker Testing
Tailoring ROS1+ NSCLC Treatment: The Role of Biomarker Testing
Physician’s Weekly spoke with Debora Bruno, MD, to explore how biomarker testing may guide treatment decisions for patients with advanced ROS1+ NSCLC.
The Role of the Multidisciplinary Team for ROS1+ NSCLC
The Role of the Multidisciplinary Team for ROS1+ NSCLC
Physician’s Weekly spoke with Edgardo Santos, MD, about the multidisciplinary team's role in developing treatment plans for patients with advanced ROS1+ NSCLC.
The Role of Pharmacists in Oncology Care
The Role of Pharmacists in Oncology Care
Physician’s Weekly spoke with Whitney Lewis, PharmD, about the evolving role of pharmacists in managing NSCLC.
Advertisement
PW QUIZ
Advertisement
Stay connected to the latest news with Physician’s Weekly
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
